Genetic basis of atherosclerosis: part II: clinical implications

Circulation. 2004 Oct 5;110(14):2066-71. doi: 10.1161/01.CIR.0000143098.98869.F8.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Apolipoprotein A-I / administration & dosage
  • Apolipoprotein A-I / genetics
  • Apolipoprotein A-I / pharmacology
  • Apolipoprotein A-I / therapeutic use
  • Arachidonate 5-Lipoxygenase / genetics
  • Arachidonate 5-Lipoxygenase / physiology
  • Arteriosclerosis / genetics*
  • Arteriosclerosis / prevention & control
  • Arteriosclerosis / therapy
  • Cohort Studies
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / prevention & control
  • Drug Evaluation, Preclinical
  • Genetic Predisposition to Disease
  • Genetic Testing
  • Genotype
  • Humans
  • Leukotrienes / metabolism
  • Life Style
  • Lipoproteins, HDL / blood
  • Lipoproteins, HDL / genetics
  • Lipoproteins, LDL / blood
  • Lipoproteins, LDL / genetics
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics
  • Methylenetetrahydrofolate Reductase (NADPH2) / physiology
  • Mice
  • Mice, Inbred C57BL
  • Multicenter Studies as Topic
  • Penetrance
  • Pharmacogenetics
  • Phospholipids / administration & dosage
  • Phospholipids / pharmacology
  • Phospholipids / therapeutic use
  • Polymorphism, Genetic
  • Promoter Regions, Genetic
  • Rabbits
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Risk

Substances

  • Apolipoprotein A-I
  • Leukotrienes
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Phospholipids
  • Recombinant Proteins
  • apolipoprotein A-I Milano
  • Arachidonate 5-Lipoxygenase
  • Methylenetetrahydrofolate Reductase (NADPH2)